Press Release: Annual General Meeting of April 30, 2024
01 May 2024 - 2:00AM
Press Release: Annual General Meeting of April 30, 2024
Annual General Meeting of April 30, 2024
- Approval of the financial
statements for the fiscal year 2023
- Distribution of a cash dividend of
€3.76 per share, with payment as of May 15, 2024
- Board composition: renewal of two
Directors and appointment of three new Independent Directors
Paris, April 30, 2024. The
Combined General Shareholders’ Meeting of Sanofi was held on
April 30, 2024, under the chairmanship of Frédéric Oudéa. All
resolutions submitted to the vote were adopted by the
shareholders.
The General Meeting approved the individual
Company and consolidated financial statements for the fiscal year
2023 and decided on the distribution of an ordinary annual dividend
of €3.76 per share. The payment of the dividend will be made on May
15, 2024.
The General Meeting also renewed Rachel Duan and
Lise Kingo as Directors, and approved the appointment of Clotilde
Delbos, Anne-Françoise Nesmes and John Sundy, all being qualified
as independent Directors.
On the proposal of the Appointments, Governance
and CSR Committee, the Board of Directors has appointed Clotilde
Delbos as member of the Audit and Compensation Committees,
Anne-Françoise Nesmes as member of the Audit Committee and John
Sundy as member of the Scientific Committee. Antoine Yver becomes
Chair of the Scientific Committee and a member of the Strategy
Review Committee.
Following the General Meeting, the Board of
Directors is temporarily composed of 17 Directors, including two
directors representing employees. It has an independence rate of
80% and a gender diversity rate of 47%. It also has 8 directors of
foreign nationality, i.e. a rate of 47 %.
The voting results and the videocast of the
Annual General Meeting are available here.
About SanofiWe are an innovative global
healthcare company, driven by one purpose: we chase the miracles of
science to improve people’s lives. Our team, across the world, is
dedicated to transforming the practice of medicine by working to
turn the impossible into the possible. We provide potentially
life-changing treatment options and life-saving vaccine protection
to millions of people globally, while putting sustainability and
social responsibility at the center of our ambitions. Sanofi is
listed on EURONEXT: SAN and NASDAQ: SNY
Media RelationsSandrine
Guendoul | + 33 6 25 09 14 25
| sandrine.guendoul@sanofi.com Nicolas
Obrist | + 33 6 77 21 27 55
| nicolas.obrist@sanofi.comVictor
Rouault | + 33 6 70 93 71 40
| victor.rouault@sanofi.com
Investor RelationsThomas Kudsk
Larsen |+ 44 7545 513 693 |
thomas.larsen@sanofi.comAlizé
Kaisserian | + 33 6 47 04 12 11 |
alize.kaisserian@sanofi.comArnaud
Delépine | + 33 6 73 69 36 93 |
arnaud.delepine@sanofi.comCorentine
Driancourt | + 33 6 40 56 92 21 |
corentine.driancourt@sanofi.comFelix
Lauscher | + 1 908 612 7239 |
felix.lauscher@sanofi.comTarik Elgoutni| + 1 617
710 3587 | tarik.elgoutni@sanofi.comNathalie
Pham | + 33 7 85 93 30 17 |
nathalie.pham@sanofi.com
Sanofi (BIT:1SAN)
Historical Stock Chart
From Apr 2024 to May 2024
Sanofi (BIT:1SAN)
Historical Stock Chart
From May 2023 to May 2024
